| Company Name | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024(F) | 2025(F) | 2026(F) | 2027(F) | 2028(F) | 2029(F) | 2030(F) | 2023 Growth($M) | 2023 Growth(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stada Arzneimittel AG | $1,462 | $1,997 | $2,241 | $2,094 | $2,065 | $2,309 | $2,325 | $2,724 | $2,680 | $2,299 | $2,368 | $2,609 | $2,751 | $2,922 | $3,432 | $2,325 | $2,289 | $2,429 | - | - | - | - | - | - | - | $140 | 6.1% |
| Grifols SA | $550 | $675 | $909 | $965 | $1,031 | $2,130 | $2,988 | $3,251 | $3,337 | $3,364 | $3,572 | $3,867 | $4,150 | $4,470 | $4,837 | $4,511 | $4,883 | $5,467 | $5,934 | $6,306 | $6,705 | $7,041 | $7,338 | $7,635 | $7,882 | $584 | 12.0% |
| Sandoz Group AG | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4,885 | $9,977 | $10,718 | $11,468 | $11,864 | $12,164 | $12,375 | $12,628 | $4,885 | #DIV/0! | |
| Fresenius SE & Co KGaA | $1,279 | $1,474 | $1,832 | $2,415 | $2,895 | $3,245 | $3,484 | $3,602 | $3,704 | $3,710 | $3,753 | $4,061 | $4,324 | $4,224 | $4,253 | $4,358 | $4,279 | $4,537 | $4,887 | $5,184 | $5,478 | $5,774 | $6,079 | $6,378 | $6,679 | $258 | 6.0% |
| Hikma Pharmaceuticals Plc | $312 | $444 | $576 | $632 | $726 | $913 | $1,103 | $1,358 | $1,480 | $1,431 | $1,941 | $1,927 | $2,066 | $2,192 | $2,334 | $2,542 | $2,504 | $2,854 | $2,984 | $3,015 | $3,152 | $3,286 | $3,399 | $3,524 | $3,647 | $350 | 14.0% |
| Lonza Group Ltd | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5,768 | $6,340 | $7,210 | $7,128 | $8,561 | $9,635 | $10,832 | $12,180 | $13,429 | $14,696 | $870 | 13.7% |
| Les Laboratoires Servier SAS | - | - | - | - | - | - | - | - | - | - | $4,431 | $4,681 | $4,928 | $5,167 | $4,626 | $5,587 | $5,127 | $5,761 | - | - | - | - | - | - | - | $634 | 12.4% |
| H. Lundbeck AS | $1,566 | $2,054 | $2,296 | $2,565 | $2,627 | $2,989 | $2,556 | $2,718 | $2,398 | $2,171 | $2,324 | $2,552 | $2,726 | $2,504 | $2,627 | $2,528 | $2,623 | $2,823 | $3,147 | $3,256 | $3,343 | $3,263 | $3,281 | $3,101 | $2,865 | $200 | 7.6% |
| Jazz Pharmaceuticals Plc | $29 | $39 | $60 | $115 | $170 | $266 | $580 | $865 | $1,164 | $1,316 | $1,477 | $1,602 | $1,870 | $2,136 | $2,346 | $3,080 | $3,641 | $3,737 | $3,806 | $4,066 | $4,423 | $4,563 | $5,128 | $5,498 | $5,877 | $96 | 2.6% |
| Boehringer Ingelheim International GmbH | $11,016 | $12,497 | $14,235 | $14,738 | $13,499 | $14,766 | $15,363 | $15,054 | $14,074 | $13,065 | $13,997 | $16,923 | $17,273 | $16,751 | $17,608 | $19,302 | $20,599 | $22,588 | - | - | - | - | - | - | - | $1,989 | 9.7% |
| Bayer AG | $10,104 | $13,885 | $15,618 | $14,183 | $13,927 | $14,348 | $14,330 | $15,771 | $17,068 | $16,789 | $19,516 | $20,217 | $20,860 | $17,846 | $17,860 | $21,056 | $19,655 | $18,820 | $19,871 | $19,919 | $19,133 | $18,854 | $19,017 | $19,244 | $18,760 | ($835) | -4.2% |
| GSK Plc | $37,263 | $38,508 | $38,455 | $37,088 | $36,105 | $35,589 | $33,795 | $33,325 | $30,763 | $27,380 | $27,961 | $28,887 | $30,887 | $31,602 | $30,866 | $33,710 | $36,143 | $37,710 | $40,150 | $42,154 | $44,678 | $46,841 | $47,600 | $48,252 | $48,388 | $1,567 | 4.3% |
| Novo Nordisk AS | $6,523 | $7,690 | $9,038 | $9,530 | $10,814 | $12,388 | $13,473 | $14,874 | $15,814 | $16,055 | $16,614 | $16,930 | $17,707 | $18,299 | $19,417 | $22,391 | $25,014 | $33,713 | $42,125 | $50,568 | $59,010 | $65,103 | $74,676 | $84,165 | $92,594 | $8,699 | 34.8% |
| Novartis AG | $29,501 | $32,711 | $35,742 | $38,455 | $42,953 | $47,987 | $46,732 | $47,468 | $47,101 | $44,328 | $41,788 | $43,085 | $44,751 | $47,446 | $48,659 | $51,626 | $50,545 | $45,689 | $47,977 | $50,258 | $51,448 | $53,191 | $54,421 | $55,727 | $56,421 | ($4,856) | -9.6% |
| AstraZeneca Plc | $25,741 | $28,713 | $30,677 | $31,905 | $32,515 | $32,981 | $27,925 | $25,712 | $26,094 | $23,641 | $21,321 | $20,152 | $21,049 | $23,565 | $25,674 | $36,399 | $42,858 | $43,458 | $49,836 | $53,333 | $55,782 | $58,646 | $61,507 | $65,461 | $70,669 | $600 | 1.4% |
| Sanofi | $35,466 | $38,996 | $35,690 | $35,969 | $34,043 | $40,052 | $38,440 | $37,236 | $37,644 | $35,079 | $34,388 | $34,750 | $35,885 | $35,195 | $36,078 | $39,352 | $39,848 | $40,975 | $44,747 | $47,840 | $50,842 | $53,855 | $56,773 | $59,151 | $61,912 | $1,127 | 2.8% |
| Roche Holding AG | $26,887 | $30,652 | $33,297 | $35,775 | $35,633 | $36,984 | $37,573 | $39,154 | $40,356 | $38,939 | $39,702 | $41,872 | $44,945 | $48,836 | $47,449 | $49,280 | $47,719 | $49,658 | $56,170 | $59,335 | $61,712 | $63,763 | $66,050 | $67,949 | $69,660 | $1,939 | 4.1% |
| UCB SA | $2,961 | $4,368 | $4,452 | $3,726 | $3,715 | $4,001 | $3,946 | $3,712 | $3,871 | $3,897 | $4,269 | $4,664 | $5,206 | $5,239 | $5,759 | $6,470 | $5,405 | $5,211 | $5,502 | $6,353 | $7,114 | $7,845 | $8,385 | $8,838 | $9,308 | ($194) | -3.6% |
| Ipsen SA | $1,025 | $1,260 | $1,428 | $1,435 | $1,248 | $1,611 | $1,552 | $1,608 | $1,674 | $1,499 | $1,734 | $1,674 | $2,627 | $2,885 | $2,954 | $3,395 | $3,182 | $3,384 | $3,585 | $3,787 | $4,023 | $4,300 | $4,404 | $4,327 | $4,336 | $202 | 6.3% |
| Merck KGaA | $7,132 | $6,107 | $7,374 | $7,424 | $7,672 | $8,235 | $8,232 | $8,398 | $7,933 | $6,770 | $6,634 | $6,865 | $7,370 | $7,518 | $7,569 | $8,383 | $8,243 | $8,709 | $9,064 | $9,313 | $9,626 | $9,472 | $9,784 | $10,162 | $10,506 | $466 | 5.7% |
Top 20 pharma Europe HQ
The ranking of the top pharmaceutical companies has been compiled from GlobalData’s pharmaceutical revenue figures, which are based on sales of prescription medicines, including generics drugs. The rankings include historical data from 2006 to 2023 and forecast data for 2024 to 2030.
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology